Xenleta™ (lefamulin) – New drug approval
August 19, 2019 - The FDA announced the approval of Nabriva Therapeutics’ Xenleta (lefamulin), for the treatment of adults with community-acquired bacterial pneumonia (CABP) caused by the following susceptible microorganisms: Streptococcus pneumoniae, Staphylococcus aureus (methicillin-susceptible isolates), Haemophilus influenzae, Legionella pneumophila, Mycoplasma pneumoniae, and Chlamydophila pneumoniae.
Top